ArticleJCO precision oncology2025

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care.

Carsten Bokemeyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.